UCI Urology Team Developing Unique Endoscope to Improve Kidney Stone Surgery

UCI Urology (four Urologists), who specialize in kidney stone diseases include Dr. Pengbo Jiang, Dr. Jaime Landman, Dr. Roshan Patel, and Dr. Ralph V. Clayman, have teamed up with UCI CALIT2 engineers, Dr. William Mao, Dr. Mike Klopfer, and G. P. Li to design a new ureteroscope that is capable of removing all kidney stone fragments during surgery.

The team has six months to complete the project and has received a grant to develop the technology.

Uci Urology, Team Developing Unique Endoscope To Improve Kidney Stone Surgery
UCI Urology Team Developing Unique Endoscope to Improve Kidney Stone Surgery

Approximately 10% of the U.S. population will experience a kidney stone. The primary treatment goals are to remove the stone with the least amount of patient discomfort and to prevent recurrence. One of the least invasive options for surgery involves using a non-incisional approach by entering the urinary tract with a ureteroscope. This type of endoscopic approach allows the urologist to access a stone and use a laser to break the stone into fragments.

Unfortunately, with the current technology, many of the smallest fragments cannot be recovered and removed. In fact, with the ureteroscope, even the best stone clearance rates are no better than 50 to 60%. The remaining fragments (about 2mm or smaller in size) can contribute to the formation of recurring stones within two years in as many as 40% of patients.

The UCI team seeks to develop instrumentation that is able to leave the kidney fragment-free following stone removal. The team’s proposal has been awarded a UCI Beall Applied Innovation Proof of Product (POP) grant, a funding program that accelerates commercially promising technology.

Dr. Ralph Clayman stated, “The POP grant has empowered and energized our work in this area. I am optimistic that given the great partnership we have with CALIT2 and the School of Engineering, within six months we will have a working prototype. This work has the potential to vastly improve surgical outcomes for all patients with kidney stones.”

The team has six months to complete this project and will utilize the Surgical Education and Research Center located at UCI Medical Center, Orange, CA. If successful, a disposable ureteroscope will be created that is able to remove all stone fragments, regardless of size. The ureteroscope will have additional features designed to improve the efficiency and effectiveness of stone removal, such as multiple laser channels and multidirectional deflection.

UCI Urology is at the forefront of research, providing patients with the best in innovative and less invasive urologic care. The department has a core mission to discover new advances in healthcare, teach tomorrow’s medical professionals, and heal patients with individualized care.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”